An Update on Monoclonal Antibody Therapy to Treat Moderate-to-Severe Asthma: Benefits, Choices, and Limitations
- 18 May 2023
- journal article
- review article
- Published by Elsevier in The American Journal of Medicine
- Vol. 136 (8) , 738-744
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Dupilumab in Persistent Asthma with Elevated Eosinophil LevelsNew England Journal of Medicine, 2013
- Eosinophils: changing perspectives in health and diseaseNature Reviews Immunology, 2012
- Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitorJournal of Experimental Medicine, 2008
- Asthma cases attributable to atopy: Results from the Third National Health and Nutrition Examination SurveyJournal of Allergy and Clinical Immunology, 2007
- Atopic Sensitization and the International Variation of Asthma Symptom Prevalence in ChildrenAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Anti-IgE therapyImmunology and Allergy Clinics of North America, 2004
- The Biology of IgE and the Basis of Allergic DiseaseAnnual Review of Immunology, 2003
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001